People · Operator
Named in public records as an officer, director or promoter · active 2022–2024 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cessation Therapeutics, Inc. | — | Biotechnology | Series A | $6.8M | $5.9M | 2022 |
| Electrum Discovery Corp. | — | Other | Pre-Seed | $3.2M | $830K | 2024 |
Eric Rasmussen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Eric Rasmussen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Williams | 1 | 27 |
| John Anderson | 1 | 22 |
| Ralph Rushton | 1 | 8 |
| DAVID HALL | 1 | 8 |
| Kevin Bales | 1 | 8 |
| Simon Ridgway | 1 | 7 |
| R. Michael Jones | 1 | 5 |
| David Genecov | 1 | 4 |
| Sharon Tetlow | 1 | 4 |
| Jeremy Martin | 1 | 3 |
| Daniel Fine | 1 | 3 |
| John Harkey | 1 | 3 |
| Jay Shepard | 1 | 3 |
| Daniel James | 1 | 2 |
| Michael Thomsen | 1 | 2 |
| Janet O'Donnell | 1 | 2 |
| Michael Skead | 1 | 1 |
| Mark Pearson | 1 | 1 |
| Andrew Barrett | 1 | 1 |
| Elena Clarici | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.